Diabetes-industry veteran Fludzinski named CEO of AmideBio

BOULDER — Pawel Fludzinski has been named chief executive of AmideBio LLC, a privately held biopharmaceutical company based in Boulder.

Fludzinski, who had been acting as a senior business advisor for the firm, has an extensive background developing drugs targeting diabetes at Eli Lilly & Co.

Misha Plam, who has served as CEO since the company’s inception, will continue as president and chairman of the board of directors.

SPONSORED CONTENT

People Powered: Preparing Longmont Businesses for Economic Success

Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.

Fludzinski said AmideBio’s novel approach to developing glucose-responsive insulins “promises to radically improve diabetes treatment.”

AmideBio has a pipeline of drug candidates targeting metabolic diseases. “AmideBio is fortunate to have found someone so well-suited to become our CEO,” Plam said. “We are at a critical time as we develop a number of drug candidates and talk with potential collaborators and investors. Dr. Fludzinski has had a distinguished career at Lilly, and fully appreciates the challenges and opportunities that the company faces. I am delighted that he has agreed to join us.”

Previously, Fludzinski was global brand development leader within the Diabetes Business Unit at Lilly, where he led a team though Phase 2, Phase 3 and global registration of Trulicity, Lilly’s once-a-week agent for glycemic control in type 2 diabetes.

Fludzinski has held multiple executive leadership positions at Lilly in the United States, United Kingdom and Japan, encompassing roles in strategy, research and drug development.